# US 2025/0144142 A1 · Methods of protecting implanted or transplanted cells and tissues from immune rejection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144142 A1
- Document ID: US20250144142A1
- Status: Published application
- Kind: A1
- Application number: 18/931,353
- Filed: 2024-10-30
- Published: 2025-05-08
- Earliest claimed: 2023-11-03
- Assignees: MUSC Foundation for Research Development; Clemson University
- Applicants: Musc Foundation for Research Development; Clemson University
- Inventors: Leonardo M.R. FERREIRA; Ying MEI; Dimitrios Chrisovalantou ARHONTOULIS; Jaime VALENTIN-QUIROGA
- Web page: https://patentgrep.com/patent/US20250144142A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/001112: {CD19 or B4}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/4211: {CD19 or B4}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 15/86: Viral vectors
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure is directed to method for the generation and use of regulatory T cells (Tregs) in the prevention and treatment of graft/transplant rejection. In particular, the method employs engineered CAR Treg cells that protect transplanted materials from rejection.

## Claims

### Claim 1

A method of protecting an implanted cell, tissue, organ or organoid from immune response in a recipient subject comprising administering to said recipient subject a chimeric antigen receptor (CAR) T regulatory cell (Treg), wherein said CAR Treg recognizes a natural or artificial antigen that (a) is not found in said implanted cell, tissue, organ or organoid and is (b) co-administered with said implanted cell, tissue, organ or organoid or found in proximity to said implanted cell, tissue, organ or organoid once implanted.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antigen is co-administered to said recipient subject and is associated with a particle (microparticle or nanoparticle), a polymer, a cell, a synthetic/engineered cell, or a synthetic cell surrogate.

### Claim 3 (depends on 1)

The method of claim 1, wherein said antigen is found in proximity to said implanted cell, tissue, organ or organoid and located on an extracellular matrix or cell found at a site of implantation in said recipient subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein said CAR Treg cells are generated from peripheral blood mononuclear cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein said CAR Treg cells are generated from cells that are CD4+, CD25+, and CD127−.

### Claim 6 (depends on 5)

The method of claim 5, wherein said CAR Treg cells are generated from naïve cells that are CD4+, CD25+, CD127−, CD45RA+, and CD62L+.

### Claim 7 (depends on 1)

The method of claim 1, wherein CAR Treg cells are generated by anti-CD3/CD28 stimulation in the presence of IL-2, followed by transduction with a virus encoding the CAR, such as a lentivirus.

### Claim 8 (depends on 1)

The method of claim 1, wherein CAR Treg cells are generated by anti-CD3/CD28 stimulation in the presence of IL-2, followed by CRISPR/Cas9 targeting of the alpha constant region of the T cell receptor (TCR) locus (TRAC) combined with transduction with a non-integrating adeno-associated virus (AAV) encoding the CAR.

### Claim 9 (depends on 7)

The method of claim 7, wherein the transduced cells are expanded in the presence of IL-2.

### Claim 10 (depends on 1)

The method of claim 1, wherein said CAR Treg cells retain expression of FOXP3 and HELIOS at levels indicative of Treg cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject is a human or non-human mammal.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject suffers from a disease or disorder benefiting from transplant therapy.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease or disorder is cardiovascular disease, cancer, autoimmune disease (e.g., Type 1 diabetes, autoimmune carditis) or Parkinson's disease.

### Claim 14 (depends on 1)

The method of claim 1, wherein said implanted cell, tissue, organ or organoid comprises cardiovascular cells, pancreatic beta cells, or dopaminergic neuron progenitors.

### Claim 15 (depends on 1)

The method of claim 1, wherein said artificial antigen is a truncated CD19 antigen.

### Claim 16

A method of transplanting a cell, tissue, organ, or organoid into a subject comprising:
(a) transplanting a cell, tissue, organ, or organoid into a subject; and
(b) introducing into the subject a chimeric antigen receptor (CAR) T regulatory cell (Treg), wherein said CAR Treg recognizes a natural or artificial antigen that (a) is not found in said implanted cell, tissue, organ or organoid and is (b) found in proximity to said implanted cell, tissue, organ or organoid once implanted.

### Claim 17 (depends on 16)

The method of claim 16, wherein said subject suffers from a disease or disorder benefiting from transplant therapy.

### Claim 18

A method of transplanting a cell, tissue, organ, or organoid into a subject comprising:
(a) transplanting a cell, tissue, organ or organoid into a subject; and
(b) administering to the subject (i) a chimeric antigen receptor (CAR) T regulatory cell (Treg), wherein said CAR Treg recognizes a natural or artificial antigen that is not found in said implanted cell, tissue, organ or organoid; and (ii) said natural or artificial antigen,
wherein said natural or artificial antigen co-administered with said CAR Treg or implanted at or near the site at which said cell, tissue, organ, or organoid is implanted.

### Claim 19 (depends on 18)

The method of claim 18, wherein said subject suffers from a disease or disorder benefiting from transplant therapy.

### Claim 20 (depends on 19)

The method of claim 19, wherein the disease or disorder is cardiovascular disease, cancer, autoimmune disease (e.g., Type 1 diabetes, autoimmune myocarditis), or Parkinson's disease.

### Claim 21

A kit comprising (a) a chimeric antigen receptor (CAR) T regulatory cell (Treg) and (b) a natural or artificial antigen recognized by said CAR Treg, optionally wherein said antigen is associated with a particle (microparticle or nanoparticle), a polymer, a cell, a synthetic cell, or a synthetic cell surrogate.

### Claim 22 (depends on 21)

The kit of claim 21, further comprising (c) a functional organoid, such as a cardiac organoid.
